993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes
Keyword(s):
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):
Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
2020 ◽
Vol 22
(6)
◽
pp. 938-946
◽
2019 ◽
Keyword(s):
2019 ◽
Keyword(s):
2020 ◽
Keyword(s):
2019 ◽
Keyword(s):
Keyword(s):
Keyword(s):
